Reports related to this article:
Project(s): View 3 related projects in PECWeb
Plant(s): View 2 related plants in PECWeb
en
Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--The west of Ireland is set to benefit from significant investments by two U.S pharmaceutical and medical device companies in the counties of Clare and Galway.
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage gene therapy company, is planning to locate its second current good manufacturing practices (cGMP) viral vector manufacturing facility and cGMP plasmid production facility at the Shannon Free Zone in County Clare. The units will comprise 94,000 square feet (sq. ft.) in two separate buildings designed to meet global regulatory requirements, including the cGMP, required by the U.S. Food and Drug Administration (FDA). Industrial Info is tracking both projects which have a combined investment value of approximately 60 million euro ($71.6 million). The first project will see the construction of the plasmid production facility followed by the viral vector manufacturing facility with a combined footprint of almost 90,000 sq. ft. The plasmid production facility is expected to be operational by the end of 2020, and the viral vector manufacturing facility by the end of 2021.
MeiraGTx stated: "These facilities will be designed for the manufacture of commercial-grade gene therapies in a fully integrated manner supported by MeiraGTx's global quality assurance organization. MeiraGTx expects the Irish facilities to provide additional flexibility as well as further large-scale capacity for clinical and commercial supply of its gene therapy product candidates from first-in-man clinical trials through potential commercialization."
Executive Director of Ireland's inward investment body, IDA, Mary Buckley, said "Today's announcement by MeiraGTx is closely aligned with IDA Ireland's strategy for the Life Sciences sector and indeed in winning jobs and investment in regional locations. This investment is an emergent area within Biopharma, and strongly endorses the Midwest's and Ireland's reputation as a key location for the next generation of biopharmaceutical manufacture."
In related news, U.S. medical device development and outsource manufacturer, Integer Holdings, has applied for planning permission to construct a new medical devices manufacturing and research and development facility in Brockagh, County Galway. The investment value is estimated at 100 million euro ($119 million) and will see the company construct the new facility near its existing facility at the IDA's Galway Business and Technology Park. The new unit will be used mainly for manufacturing guidewires and catheters. The company, which employs around 360 people in Galway, also opened its Galway Research and Development (R&D) Innovation Centre in the county in June.
At the time, Payman Khales, president of Integer's cardio and vascular business, said: "The Galway R&D Innovation Centre will allow us to enhance our current capabilities, while accelerating the development of a broad range of cardio and vascular products. Located in Claregalway, six kilometers from Integer's main Galway, Ireland, facility, the new, fully dedicated 8,500 square foot facility will support Integer's customers across the globe, including the significant medical device cluster in Ireland. The facility features a versatile workspace for the R&D team to collaborate with customers on innovative technical solutions that meet their evolving needs. There is also a significant increase in development lab space, providing the team room to grow and add capabilities, including space for a cleanroom pilot line. In addition, the opening of this new dedicated facility, frees up space allowing the Galway manufacturing site to expand, increase capacity and add new equipment as required to meet customers' needs."
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Our European headquarters are located in Galway, Ireland. Follow IIR Europe on: Facebook - Twitter - LinkedIn For more information on our European coverage send inquiries to info@industrialinfo.eu or visit us online at Industrial Info Europe.
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage gene therapy company, is planning to locate its second current good manufacturing practices (cGMP) viral vector manufacturing facility and cGMP plasmid production facility at the Shannon Free Zone in County Clare. The units will comprise 94,000 square feet (sq. ft.) in two separate buildings designed to meet global regulatory requirements, including the cGMP, required by the U.S. Food and Drug Administration (FDA). Industrial Info is tracking both projects which have a combined investment value of approximately 60 million euro ($71.6 million). The first project will see the construction of the plasmid production facility followed by the viral vector manufacturing facility with a combined footprint of almost 90,000 sq. ft. The plasmid production facility is expected to be operational by the end of 2020, and the viral vector manufacturing facility by the end of 2021.
MeiraGTx stated: "These facilities will be designed for the manufacture of commercial-grade gene therapies in a fully integrated manner supported by MeiraGTx's global quality assurance organization. MeiraGTx expects the Irish facilities to provide additional flexibility as well as further large-scale capacity for clinical and commercial supply of its gene therapy product candidates from first-in-man clinical trials through potential commercialization."
Executive Director of Ireland's inward investment body, IDA, Mary Buckley, said "Today's announcement by MeiraGTx is closely aligned with IDA Ireland's strategy for the Life Sciences sector and indeed in winning jobs and investment in regional locations. This investment is an emergent area within Biopharma, and strongly endorses the Midwest's and Ireland's reputation as a key location for the next generation of biopharmaceutical manufacture."
In related news, U.S. medical device development and outsource manufacturer, Integer Holdings, has applied for planning permission to construct a new medical devices manufacturing and research and development facility in Brockagh, County Galway. The investment value is estimated at 100 million euro ($119 million) and will see the company construct the new facility near its existing facility at the IDA's Galway Business and Technology Park. The new unit will be used mainly for manufacturing guidewires and catheters. The company, which employs around 360 people in Galway, also opened its Galway Research and Development (R&D) Innovation Centre in the county in June.
At the time, Payman Khales, president of Integer's cardio and vascular business, said: "The Galway R&D Innovation Centre will allow us to enhance our current capabilities, while accelerating the development of a broad range of cardio and vascular products. Located in Claregalway, six kilometers from Integer's main Galway, Ireland, facility, the new, fully dedicated 8,500 square foot facility will support Integer's customers across the globe, including the significant medical device cluster in Ireland. The facility features a versatile workspace for the R&D team to collaborate with customers on innovative technical solutions that meet their evolving needs. There is also a significant increase in development lab space, providing the team room to grow and add capabilities, including space for a cleanroom pilot line. In addition, the opening of this new dedicated facility, frees up space allowing the Galway manufacturing site to expand, increase capacity and add new equipment as required to meet customers' needs."
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Our European headquarters are located in Galway, Ireland. Follow IIR Europe on: Facebook - Twitter - LinkedIn For more information on our European coverage send inquiries to info@industrialinfo.eu or visit us online at Industrial Info Europe.
